U.S. Markets closed

Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3

·1 min read
Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Biogen Inc. were up 1.8% in premarket trading on Wednesday after the company beat expectations for the third quarter despite lower-than-expected utilization of Aduhelm, its controversial and closely watched new Alzheimer's disease treatment. Biogen had net income of $329.2 million, or $2.22 per share, in the third quarter of 2021, compared with net income of $701.5 million, or $4.47 per share, in the same quarter a year ago. Adjusted earnings per share were $4.47, against a FactSet con